1 | 16,5% Cutaquig | - | - | - | - | 1件: 65 65 |
2 | 2(S)-(ACETYLAMINO)-4-METHYLPENTANOIC ACID | - | - | - | - | 2件: 19 19, 65 |
3 | 36-482-Hyaluronoglucosaminidase PH20 (rHuPH20) | 1件: Hyaluronidase Hyaluronidase | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
4 | A10BK03 | - | - | - | - | 1件: 65 65 |
5 | Abatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 26件: 11 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 |
6 | Acoziborole | - | - | - | - | 1件: 65 65 |
7 | Acoziborole (SCYX-7158) | 1件: SCYX-7158 SCYX-7158 | - | - | - | 1件: 65 65 |
8 | ADA gene transfer | - | - | - | - | 1件: 65 65 |
9 | ADA PBSC | - | - | - | - | 1件: 65 65 |
10 | ADA Umbilical Cord Blood Cells | - | - | - | - | 1件: 65 65 |
11 | Adagen | 1件: Pegademase Pegademase | 1件: D05384
D05384
| - | - | 1件: 65 65 |
12 | Adenosine | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 3件: 13 13, 58, 65 |
13 | Administration of drug (Interferon-gamma 1-b) subcutaneously | - | - | - | - | 1件: 65 65 |
14 | Adverse Reactions of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 |
15 | Adverse Reactions of Gammagard subcutaneously at Week 24 | - | - | - | - | 1件: 65 65 |
16 | Adverse Reactions of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 |
17 | Adverse Reactions of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 |
18 | Adverse Reactions of Gammagard subdermally at Week 24 | - | - | - | - | 1件: 65 65 |
19 | Adverse Reactions of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 |
20 | ALDESLEUKIN | 1件: Aldesleukin Aldesleukin | 1件: D00748
D00748
| 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 4件: 49 49, 65, 96, 97 |
21 | Alefacept | 1件: Alefacept Alefacept | 1件: D02800
D02800
| 1件: CD58 CD58 💬 | 2件: Cell adhesion molecules Cell adhesion molecules, Epstein-Barr virus infection 💬 | 6件: 37 37, 60, 65, 164, 284, 285 |
22 | ALEMTUZUMAB | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 17件: 13 13, 15, 19, 20, 36, 43, 44, 46, 51, 60, 63, 65, 85, 96, 164, 283, 284 |
23 | Alemtuzumab 0.2 mg | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 |
24 | Alemtuzumab 0.3 mg | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 2件: 65 65, 164 |
25 | Alentuzumab (Campath) | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 65 65 |
26 | Allo BMT | - | - | - | - | 1件: 65 65 |
27 | Allogeneic Bone Marrow Transplantation | - | - | - | - | 9件: 60 60, 62, 65, 96, 164, 283, 284, 285, 286 |
28 | Allogeneic hematopoietic stem cell transplantation | - | - | - | - | 8件: 28 28, 51, 60, 62, 65, 164, 284, 285 |
29 | Allogeneic HSC | - | - | - | - | 1件: 65 65 |
30 | Allogeneic HSCT | - | - | - | - | 1件: 65 65 |
31 | Allogeneic peripheral blood stem cell | - | - | - | - | 1件: 65 65 |
32 | Anti-CD45 | - | - | - | - | 3件: 60 60, 65, 285 |
33 | Anti-Thymocyte Globulin | - | - | - | - | 18件: 11 11, 13, 14, 36, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 164, 283, 284, 285 |
34 | Anti-Thymocyte Globulin (Rabbit) | 1件: Rabbit Rabbit | - | - | - | 4件: 60 60, 65, 96, 285 |
35 | Antithymocyte Globulin | - | - | - | - | 3件: 60 60, 65, 284 |
36 | AProArt | - | - | - | - | 1件: 65 65 |
37 | Argininhydrochlorid | - | - | - | - | 1件: 65 65 |
38 | Asceniv™ | - | - | - | - | 1件: 65 65 |
39 | Asparaginase | 1件: Asparaginase Escherichia coli Asparaginase Escherichia coli | 1件: D02997
D02997
| - | - | 1件: 65 65 |
40 | Autologous CD34+ cell transduced with G2SCID vector | - | - | - | - | 1件: 65 65 |
41 | AUTOLOGOUS CD34+ CELLS TRANSDUCED EX-VIVO WITH THE PCCLCHIMGP91/VSVG LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 |
42 | Autologous CD34+ cells transduced with the Lentiviral vector containing the human Wiskott Aldrich Sy | - | - | - | - | 1件: 65 65 |
43 | Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence | - | - | - | - | 1件: 65 65 |
44 | Autologous CD34+ HSCs transduced ex vivo with EFS lentiviral vector encoding for the human ADA gene | - | - | - | - | 1件: 65 65 |
45 | AUTOLOGOUS CD34+CELLS TRANSDUCED WITH THE W1.6_HWASP_WPRE (VSVG) LENTIVIRAL VECTOR | - | - | - | - | 1件: 65 65 |
46 | Autologous ex vivo gene therapy products based on the EFS LV encoding for the human adenosine deaminase (ADA) gene (EFS-ADA LV) | 1件: Adenosine Adenosine | 1件: D00045
D00045
| 4件: ADORA1 ADORA1, ADORA2A, ADORA2B, ADORA3 💬 | 12件: Alcoholism Alcoholism, Calcium signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 |
47 | Azathioprine | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 21件: 6 6, 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 63, 65, 66, 85, 93, 94, 95, 96, 97, 162 |
48 | B-Lymphocyte Stimulator (BLyS) | - | - | - | - | 1件: 65 65 |
49 | Baclofen | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 7件: 2 2, 10, 13, 18, 65, 149, 206 |
50 | Bacteriophage | - | - | - | - | 1件: 65 65 |
51 | Benznidazole | 1件: Benznidazole Benznidazole | 1件: D02489
D02489
| - | - | 1件: 65 65 |
52 | Biological sampling | - | - | - | - | 1件: 65 65 |
53 | Bivigam | - | - | - | - | 1件: 65 65 |
54 | Blood draw | - | - | - | - | 5件: 6 6, 19, 65, 231, 299 |
55 | Blood sample | - | - | - | - | 18件: 8 8, 13, 46, 49, 51, 53, 61, 65, 66, 84, 96, 97, 107, 127, 235, 274, 288, 299 |
56 | BMS-188667 | - | - | - | - | 9件: 46 46, 49, 53, 65, 96, 97, 107, 222, 271 |
57 | BPX-501 T cells | - | - | - | - | 4件: 65 65, 284, 285, 326 |
58 | BT090 | - | - | - | - | 1件: 65 65 |
59 | BT524 | - | - | - | - | 1件: 65 65 |
60 | BT595 | - | - | - | - | 2件: 63 63, 65 |
61 | BT681 | - | - | - | - | 1件: 65 65 |
62 | BUSILVEX | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 4件: 19 19, 36, 60, 65 |
63 | BUSILVEX - 6 MG/ML - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 10 ML 8 FLACONCINI | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 2件: 19 19, 65 |
64 | Busulfan | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 13件: 19 19, 20, 28, 36, 49, 51, 60, 65, 164, 274, 284, 285, 326 |
65 | Busulfan IV | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 1件: 65 65 |
66 | Busulfan test dose | 1件: Busulfan Busulfan | 1件: D00248
D00248
| - | - | 1件: 65 65 |
67 | Busulfan, Cyclophosphamide, ATG, GCSF | 2件: Busulfan Busulfan, Cyclophosphamide | 3件: D00248
D00248
,
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
68 | Busulfan, Fludarabine and ATG | 2件: Busulfan Busulfan, Fludarabine | 3件: D00248
D00248
,
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
69 | Busulfan, Fludarabine, ATG, TLI | 2件: Busulfan Busulfan, Fludarabine | 3件: D00248
D00248
,
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 284 |
70 | C1 ESTERASE INHIBITOR (HUMAN) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
71 | C1 Esterase Inhibitor Human | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
72 | C1 inhibitor | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
73 | C1 inhibitor concentrate | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
74 | C1-esterase inhibitor [recombinant] (C1-INH-R) | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
75 | C1-INH | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
76 | Campath | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 12件: 19 19, 20, 49, 51, 60, 62, 65, 164, 234, 283, 285, 326 |
77 | Campath -1H | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 65 65 |
78 | Campath 1H | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 4件: 60 60, 65, 164, 285 |
79 | Campath, Fludarabine, Cyclophosphamide | 2件: Cyclophosphamide Cyclophosphamide, Fludarabine | 4件: D00287
D00287
,
D01907
,
D07760
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 284 |
80 | Catapresan | - | - | - | - | 2件: 65 65, 78 |
81 | Catapresan 75, Tabletten | - | - | - | - | 1件: 65 65 |
82 | CD3/CD19 neg allogeneic BMT | - | - | - | - | 1件: 65 65 |
83 | CD3/CD19 negative allogeneic hematopoietic stem cells | - | - | - | - | 1件: 65 65 |
84 | CD34 Stem Cell Selection Therapy | - | - | - | - | 3件: 60 60, 65, 284 |
85 | CD34+ | - | - | - | - | 1件: 65 65 |
86 | CD34+ cells transduced with ADA retrovir | - | - | - | - | 1件: 65 65 |
87 | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 |
88 | CD34+CELLS | - | - | - | - | 2件: 65 65, 285 |
89 | CDZ173 | - | - | - | - | 2件: 53 53, 65 |
90 | Cell processing for TCRabeta+/CD19+ depletion | - | - | - | - | 1件: 65 65 |
91 | Cell processing for TCRaß+/CD19+ depletion | - | - | - | - | 1件: 65 65 |
92 | Chemotherapy, intrathecal chemotherapy, steroid therapy | - | - | - | - | 1件: 65 65 |
93 | Chloride | 1件: Chloride ion Chloride ion | - | - | - | 29件: 6 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 97, 107, 127, 168, 171, 193, 227, 228, 251, 271, 288, 296, 297, 299, 338 |
94 | Chrono Super PID then Generic Syringe-Gammanorm | - | - | - | - | 1件: 65 65 |
95 | CliniMACS | - | - | - | - | 2件: 60 60, 65 |
96 | CliniMACS® CD34 Reagent System cell sorter device | - | - | - | - | 1件: 65 65 |
97 | Clonidine | 1件: Clonidine Clonidine | 2件: D00281
D00281
,
D00604
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 4件: 6 6, 65, 70, 78 |
98 | Clonidinhydrochlorid | - | - | - | - | 1件: 65 65 |
99 | Collection of samples | - | - | - | - | 4件: 49 49, 65, 95, 107 |
100 | Conjugated pneumococcal vaccine (Prevenar) | - | - | - | - | 1件: 65 65 |
101 | Continuous Glucose Monitor | 2件: Dextrose, unspecified form Dextrose, unspecified form, Methamidophos | - | - | - | 1件: 65 65 |
102 | COVID-19 Vaccine Moderna | 1件: Moderna COVID-19 Vaccine Moderna COVID-19 Vaccine | 1件: D12114
D12114
| - | - | 4件: 46 46, 51, 65, 299 |
103 | Cryopreserved EFS-ADA LV transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
104 | Cryopreserved G2SCID lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
105 | CT Scan | - | - | - | - | 1件: 65 65 |
106 | Cultured Thymus Tissue | - | - | - | - | 1件: 65 65 |
107 | Cultured Thymus Tissue for Implantation (CTTI) | - | - | - | - | 1件: 65 65 |
108 | Cultured Thymus Tissue Implantation (CTTI) | - | - | - | - | 1件: 65 65 |
109 | CUTAQUIG | - | - | - | - | 1件: 65 65 |
110 | CUVITRU | - | - | - | - | 1件: 65 65 |
111 | Cuvitru 200 mg/ml solution for subcutaneous injection | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
112 | Cyclophosphamide | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 45件: 11 11, 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 205, 222, 224, 256, 265, 274, 283, 284, 285, 288, 326, 331 |
113 | Cyclophosphamide (Cytoxan) | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 65 65 |
114 | Cyclophosphamide 30 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 3件: 65 65, 285, 326 |
115 | Cyclophosphamide 40 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 3件: 65 65, 285, 326 |
116 | Cyclophosphamide Dose Level 1 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
117 | Cyclophosphamide Dose Level 2 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
118 | Cyclophosphamide Dose Level 3 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
119 | Cyclophosphamide Dose Level 4 | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 2件: 65 65, 284 |
120 | Cyclophosphamide post transplant | 1件: Cyclophosphamide Cyclophosphamide | 2件: D00287
D00287
,
D07760
| - | - | 1件: 65 65 |
121 | Cyclosporine | 1件: Cyclosporine Cyclosporine | 1件: D00184
D00184
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 37件: 11 11, 19, 20, 28, 36, 38, 39, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 61, 62, 63, 64, 65, 90, 95, 97, 107, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
122 | Cyclosporins | - | - | - | - | 4件: 53 53, 60, 65, 222 |
123 | Cytarabine | 1件: Cytarabine Cytarabine | 3件: D00168
D00168
,
D03046
,
D03637
| - | - | 7件: 11 11, 13, 14, 25, 49, 60, 65 |
124 | DACLIZUMAB | 1件: Daclizumab Daclizumab | 1件: D03639
D03639
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 8件: 13 13, 56, 60, 65, 97, 107, 283, 284 |
125 | Danazol | 1件: Danazol Danazol | 1件: D00289
D00289
| 3件: AR AR, ESR1, PGR 💬 | 12件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 5件: 60 60, 63, 64, 65, 285 |
126 | Data collection | - | - | - | - | 1件: 65 65 |
127 | Daunorubicin | 1件: Daunorubicin Daunorubicin | 2件: D01264
D01264
,
D07776
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 1件: 65 65 |
128 | DB289 | - | - | - | - | 1件: 65 65 |
129 | Depletion in CD45RA graft donor | - | - | - | - | 1件: 65 65 |
130 | Dexametasone Fosfato Sodico | - | - | - | - | 1件: 65 65 |
131 | Dexamethasone | 1件: Dexamethasone Dexamethasone | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 25件: 13 13, 14, 16, 28, 35, 46, 53, 63, 64, 65, 70, 74, 75, 81, 84, 90, 96, 97, 162, 222, 235, 257, 283, 296, 299 |
132 | Dexamethasone 21-dihydrogen phosphate | 3件: Dexamethasone Dexamethasone, Hydrogen, Phosphate ion | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 |
133 | DEXAMETHASONE SODIUM PHOSPHATE | 2件: Dexamethasone Dexamethasone, Phosphate ion | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 3件: 65 65, 70, 96 |
134 | Dexamethasone sodium phosphate (soluzione 25mg/ml) | 2件: Dexamethasone Dexamethasone, Phosphate ion | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 |
135 | DEXAMETHASONE SODIUM PHOSPHATE PH. EUR. | 2件: Dexamethasone Dexamethasone, Phosphate ion | 9件: D00292
D00292
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 |
136 | Dexamethasone, procarbazine | 2件: Dexamethasone Dexamethasone, Procarbazine | 11件: D00292
D00292
,
D00478
,
D00975
,
D01510
,
D01615
,
D01632
,
D01948
,
D02174
,
D02591
,
D02592
,
D08423
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 |
137 | Dextrose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 5件: 56 56, 60, 65, 70, 226 |
138 | Dextrose, 5% in Water | 2件: Dextrose, unspecified form Dextrose, unspecified form, Water | 1件: D00001
D00001
| - | - | 1件: 65 65 |
139 | Diagnostic Test: blood drawing in healthy controls | - | - | - | - | 1件: 65 65 |
140 | Diagnostic Test: blood drawing in patients with WAS | - | - | - | - | 1件: 65 65 |
141 | Diagnostic Test: functional and antigenic C1 inhibitor | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
142 | Diagnostic Test: Oral glucose tolerance test | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 3件: 13 13, 65, 299 |
143 | Diagnostic Test: RNA and neopterin detection | 1件: Neopterin Neopterin | - | - | - | 1件: 65 65 |
144 | Dihydrogen | 1件: Hydrogen Hydrogen | - | - | - | 1件: 65 65 |
145 | Donor peripheral blood stem cells. | - | - | - | - | 1件: 65 65 |
146 | Doxorubicin | 1件: Doxorubicin Doxorubicin | 1件: D03899
D03899
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 5件: 26 26, 28, 34, 65, 331 |
147 | Doxorubicin, methotrexate, cyclophosphamide, L-asparaginase | 4件: Asparaginase Escherichia coli Asparaginase Escherichia coli, Cyclophosphamide, Doxorubicin, Methotrexate | 6件: D00142
D00142
,
D00287
,
D02115
,
D02997
,
D03899
,
D07760
| 4件: DHFR DHFR, DHFR2, TOP2A, TOP2B 💬 | 6件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate, Platinum drug resistance 💬 | 1件: 65 65 |
148 | EDS-EP dose range of ~14-22 mg DSP/infusion | - | - | - | - | 1件: 65 65 |
149 | EDS-EP dose range of ~5-10 mg DSP/infusion | - | - | - | - | 1件: 65 65 |
150 | EF1aS-ADA lentiviral vector gene modified autologous CD34+ cells | - | - | - | - | 1件: 65 65 |
151 | EF1aS-ADA lentiviral vector transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
152 | Efficacy of Gammagard subcutaneously at Week 12 | - | - | - | - | 1件: 65 65 |
153 | Efficacy of Gammagard subcutaneously at Week 24 | - | - | - | - | 1件: 65 65 |
154 | Efficacy of Gammagard subcutaneously at Week 36 | - | - | - | - | 1件: 65 65 |
155 | Efficacy of Gammagard subdermally at Week 12 | - | - | - | - | 1件: 65 65 |
156 | Efficacy of Gammagard subdermally at Week 24 | - | - | - | - | 1件: 65 65 |
157 | Efficacy of Gammagard subdermally at Week 36 | - | - | - | - | 1件: 65 65 |
158 | Eflornithine | 1件: Eflornithine Eflornithine | 1件: D07883
D07883
| 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 |
159 | Eflornithine plus Nifurtimox combination therapy | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: D00833
D00833
,
D07883
| 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 |
160 | Elapegademase | 1件: Elapegademase Elapegademase | 1件: D11017
D11017
| 1件: ADA ADA 💬 | 3件: Metabolic pathways Metabolic pathways, Primary immunodeficiency, Purine metabolism 💬 | 1件: 65 65 |
161 | Elapegademase-lvlr | 1件: Elapegademase Elapegademase | 1件: D11017
D11017
| 1件: ADA ADA 💬 | 3件: Metabolic pathways Metabolic pathways, Primary immunodeficiency, Purine metabolism 💬 | 1件: 65 65 |
162 | ELTROMBOPAG | 1件: Eltrombopag Eltrombopag | - | - | - | 5件: 60 60, 63, 65, 284, 285 |
163 | Empagliflozin | 1件: Empagliflozin Empagliflozin | 1件: D10459
D10459
| 1件: SLC5A2 SLC5A2 💬 | - | 5件: 65 65, 72, 96, 97, 257 |
164 | EP2006 | - | - | - | - | 1件: 65 65 |
165 | EP2006 (Filgrastim) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
166 | Estradiol | 1件: Estradiol Estradiol | 8件: D00105
D00105
,
D01413
,
D01617
,
D01953
,
D04061
,
D04063
,
D04064
,
D04065
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 7件: 13 13, 46, 49, 65, 76, 226, 299 |
167 | Estradiol valerate | 2件: Estradiol Estradiol, Estradiol valerate | 8件: D00105
D00105
,
D01413
,
D01617
,
D01953
,
D04061
,
D04063
,
D04064
,
D04065
| 2件: ESR1 ESR1, ESR2 💬 | 10件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway 💬 | 1件: 65 65 |
168 | Estradiolvalerat | - | - | - | - | 1件: 65 65 |
169 | Etoposide | 1件: Etoposide Etoposide | 2件: D00125
D00125
,
D04107
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 11件: 11 11, 13, 14, 26, 28, 34, 60, 65, 85, 164, 331 |
170 | Etoposide, cytarabine, mercaptopurine | 3件: Cytarabine Cytarabine, Etoposide, Mercaptopurine | 7件: D00125
D00125
,
D00161
,
D00168
,
D03046
,
D03637
,
D04107
,
D04931
| 3件: HPRT1 HPRT1, TOP2A, TOP2B 💬 | 4件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Platinum drug resistance, Purine metabolism 💬 | 1件: 65 65 |
171 | Ex vivo culture and transduction of the patient's autologous CD34+ HSC with lentivirus vector VSV-G pseudotyped CL20- 4i-EF1alpha-hgammac-OPT vector | - | - | - | - | 1件: 65 65 |
172 | EZN-2279 | - | - | - | - | 1件: 65 65 |
173 | Fansidar (pyrimethamine and sulfadoxine) | 2件: Pyrimethamine Pyrimethamine, Sulfadoxine | 2件: D00488
D00488
,
D00580
| - | - | 1件: 65 65 |
174 | Fexinidazole | 1件: Fexinidazole Fexinidazole | 1件: D11252
D11252
| - | - | 1件: 65 65 |
175 | Fibrinogen | 1件: Fibrinogen human Fibrinogen human | - | - | - | 3件: 14 14, 65, 288 |
176 | Fibrinogen (coagulation factorI) | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 |
177 | Fibrinogen Concentrate from Human Plasma | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 |
178 | Filgrastim | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 28件: 2 2, 6, 13, 25, 26, 28, 34, 35, 38, 40, 41, 42, 45, 46, 49, 51, 60, 62, 65, 96, 113, 164, 256, 283, 284, 285, 296, 331 |
179 | Filgrastim Hexal | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
180 | Filgrastim, Alemtuzumab | 2件: Alemtuzumab Alemtuzumab, Filgrastim | 2件: D02802
D02802
,
D03235
| 2件: CD52 CD52, CSF3R 💬 | 6件: , Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
181 | Flebogamma 5% DIF | - | - | - | - | 1件: 65 65 |
182 | Fludarabina | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 19 19, 65 |
183 | Fludarabina Accord | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
184 | FLUDARABINA TEVA - 25 MG/ML CONCENTRATO PER SOLUZIONE INIETTABILE O PER INFUSIONE 1 FLACONCINO DI VETRO DA 2 ML | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
185 | Fludarabine | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 18件: 13 13, 28, 36, 46, 49, 51, 60, 61, 62, 65, 85, 96, 164, 283, 284, 285, 286, 326 |
186 | Fludarabine monophosphate | 1件: Fludarabine Fludarabine | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 3件: 65 65, 284, 326 |
187 | Fludarabine phosphate | 2件: Fludarabine Fludarabine, Phosphate ion | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 12件: 28 28, 36, 49, 51, 60, 62, 65, 96, 283, 284, 285, 286 |
188 | Fludarabine phosphate 30 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 |
189 | Fludarabine phosphate 40 mg | 2件: Fludarabine Fludarabine, Phosphate ion | 2件: D01907
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 |
190 | Fludarabine, Busulfan, Thymoglobulin | 3件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit), Busulfan, Fludarabine | 3件: D00248
D00248
,
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
191 | Fludarabine, Melphalan, Thiotepa | 3件: Fludarabine Fludarabine, Melphalan, Thiotepa | 4件: D00369
D00369
,
D00583
,
D01907
,
D07966
| 1件: RRM1 RRM1 💬 | 5件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 1件: 65 65 |
192 | FORTECORTIN | - | - | - | - | 2件: 28 28, 65 |
193 | Fortecortin Inject 40 mg Amp. | - | - | - | - | 1件: 65 65 |
194 | Fucose | 1件: Fucose Fucose | - | - | - | 1件: 65 65 |
195 | G-CSF | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 16件: 2 2, 6, 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331 |
196 | G-CSF for Conditioning before HSCT. | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
197 | G1XCG | - | - | - | - | 1件: 65 65 |
198 | G1XCGD transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
199 | Gadolinium | 1件: Gadolinium Gadolinium | - | - | - | 6件: 13 13, 34, 46, 58, 65, 86 |
200 | Gadolinium For abdomen | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 |
201 | Gadolinium For lower back | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 |
202 | GAMMAGARD LIQUID | - | - | - | - | 1件: 65 65 |
203 | Gammagard S/D (Solvent/Detergent) | - | - | - | - | 1件: 65 65 |
204 | Gammaglobulin | - | - | - | - | 1件: 65 65 |
205 | Gammanorm | - | - | - | - | 2件: 14 14, 65 |
206 | Gammanorm 165 mg/mL | - | - | - | - | 1件: 65 65 |
207 | Gammaplex | - | - | - | - | 2件: 63 63, 65 |
208 | Gammaplex (5%) | - | - | - | - | 1件: 65 65 |
209 | Gammaplex (Intravenous immunoglobulin) | - | - | - | - | 1件: 65 65 |
210 | Gammaplex 10 | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
211 | GAMUNEX-C | - | - | - | - | 1件: 65 65 |
212 | Gcsf | - | - | - | - | 1件: 65 65 |
213 | Gene Therapy Method for CGD | - | - | - | - | 1件: 65 65 |
214 | Gene transfer | - | - | - | - | 1件: 65 65 |
215 | Gene-Transduced Autologous CD34+ Stem Cells | - | - | - | - | 1件: 65 65 |
216 | Generic Syringe then Chrono Super PID-Gammanorm | - | - | - | - | 1件: 65 65 |
217 | Genetic: CL20-i4-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 |
218 | Genetic: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) | - | - | - | - | 1件: 65 65 |
219 | Genetic: Infusion of autologous EFS-ADA LV CD34+ (OTL-101) | - | - | - | - | 1件: 65 65 |
220 | Genetic: Infusion of autologous EFS-ADA LV CD34+ cells | - | - | - | - | 1件: 65 65 |
221 | Genetically modified autologous blood stem cells | - | - | - | - | 1件: 65 65 |
222 | Glucose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 15件: 2 2, 6, 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 |
223 | Glycolic acid | 1件: Glycolic acid Glycolic acid | - | - | - | 1件: 65 65 |
224 | Glycosade | - | - | - | - | 3件: 65 65, 256, 257 |
225 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318 |
226 | Gp91 Grans | - | - | - | - | 1件: 65 65 |
227 | Granulocyte Colony Stimulating Factor | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 6件: 2 2, 28, 36, 57, 65, 85 |
228 | Granulocyte colony stimulating factor (G-CSF) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
229 | GTG003.08 | - | - | - | - | 1件: 65 65 |
230 | GVHD Prophylaxis | - | - | - | - | 2件: 60 60, 65 |
231 | Haemocomplettan P | - | - | - | - | 1件: 65 65 |
232 | Haemocomplettan(R) P | - | - | - | - | 1件: 65 65 |
233 | Haemocomplettan(R) P 1g/2g | - | - | - | - | 1件: 65 65 |
234 | Haplo BM with T cell depletion | - | - | - | - | 1件: 65 65 |
235 | Haploidentical Hematopoietic Cell Transplantation | - | - | - | - | 2件: 60 60, 65 |
236 | Hematopoetic Stem Cell Transplantation | - | - | - | - | 5件: 19 19, 65, 120, 160, 326 |
237 | Hematopoietic Stem Cell Transplant | - | - | - | - | 2件: 65 65, 285 |
238 | Hematopoietic Stem Cell Transplantation | - | - | - | - | 13件: 11 11, 13, 14, 19, 20, 35, 46, 49, 51, 65, 96, 234, 285 |
239 | Hizentra | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 14 14, 50, 51, 65 |
240 | Hizentra® | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 |
241 | Horse -Anti-thymocyte | - | - | - | - | 1件: 65 65 |
242 | HTLP | - | - | - | - | 1件: 65 65 |
243 | HUMAN FIBRINOGEN | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 |
244 | Human Fibrinogen Concentrate | 1件: Fibrinogen human Fibrinogen human | - | - | - | 1件: 65 65 |
245 | Human Immunglobulin G (IgG) | - | - | - | - | 1件: 65 65 |
246 | Human Immunoglobulin | - | - | - | - | 2件: 63 63, 65 |
247 | HUMAN IMMUNOGLOBULIN G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 14 14, 50, 63, 65 |
248 | Human normal immunoglobulin | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 9件: 11 11, 13, 14, 43, 45, 50, 51, 63, 65 |
249 | HUMAN NORMAL IMMUNOGLOBULIN (IV) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 63, 65 |
250 | Human normal immunoglobulin (IVIg) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 50, 65 |
251 | Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
252 | Human normal immunoglobulin (subcutaneous) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
253 | HUMAN NORMAL IMMUNOGLOBULIN FOR | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
254 | Human normal immunoglobulin for intravenous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 51, 65 |
255 | HUMAN NORMAL IMMUNOGLOBULIN FOR INTRAVENOUS USE | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 63 63, 65 |
256 | Human normal immunoglobulin for intravenous use (IVIG) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
257 | Human normal immunoglobulin for subcutaneous administration | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 51 51, 65 |
258 | Human Normal Immunoglobulin for Subcutaneous Administration (IGSC) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
259 | Human normal immunoglobulin G (IgG > 98% purity) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 |
260 | Human T Lymphoid Progenitor (HTLP) injection | - | - | - | - | 1件: 65 65 |
261 | Hyaluronidase | 1件: Hyaluronidase Hyaluronidase | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 5件: 14 14, 28, 51, 65, 331 |
262 | Hyaluronoglucosaminidase | 1件: Hyaluronidase Hyaluronidase | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
263 | Hydroxyurea | 1件: Hydroxyurea Hydroxyurea | 1件: D00341
D00341
| 1件: RRM2 RRM2 💬 | 6件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism, p53 signaling pathway 💬 | 8件: 3 3, 13, 19, 20, 65, 85, 86, 284 |
264 | HyQvia | 1件: Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) | - | - | - | 2件: 14 14, 65 |
265 | HyQvia 100 mg/ml solution for infusion for subcutaneous use | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
266 | I10E | - | - | - | - | 3件: 14 14, 63, 65 |
267 | IB 1001 | - | - | - | - | 1件: 65 65 |
268 | IB1001 | - | - | - | - | 2件: 19 19, 65 |
269 | Ibuprofen | 1件: Ibuprofen Ibuprofen | 4件: D00126
D00126
,
D01122
,
D04490
,
D06606
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 7件: 13 13, 46, 65, 107, 113, 271, 299 |
270 | IFN-gamma | - | - | - | - | 1件: 65 65 |
271 | Ig VENA 50 g/l solution for infusion 100 ml vial + infusion set | - | - | - | - | 2件: 63 63, 65 |
272 | IgG Next Generation | - | - | - | - | 2件: 63 63, 65 |
273 | IgG Next Generation (BT595) | - | - | - | - | 1件: 65 65 |
274 | IgHy10 | - | - | - | - | 1件: 65 65 |
275 | IGIV, 10% | - | - | - | - | 2件: 14 14, 65 |
276 | IGIV-C 10% | - | - | - | - | 1件: 65 65 |
277 | IgNextGen 16% | - | - | - | - | 1件: 65 65 |
278 | IGNG | - | - | - | - | 1件: 65 65 |
279 | IgPro10 | - | - | - | - | 3件: 14 14, 51, 65 |
280 | IgPro20 | - | - | - | - | 4件: 14 14, 50, 51, 65 |
281 | IGSC 20% | - | - | - | - | 1件: 65 65 |
282 | IGSC 20% 150 mg/kg | - | - | - | - | 1件: 65 65 |
283 | IGSC 20% daily push versus 2 times per week pump | - | - | - | - | 1件: 65 65 |
284 | IGSC 20% daily push versus every 2 weeks pump | - | - | - | - | 1件: 65 65 |
285 | IGSC 20% daily push versus once a week pump | - | - | - | - | 1件: 65 65 |
286 | IGSC 20% infusion | - | - | - | - | 1件: 65 65 |
287 | IGSC, 16% | - | - | - | - | 1件: 65 65 |
288 | IGSC, 20% | - | - | - | - | 1件: 65 65 |
289 | Immune Globulin Infusion (Human), 10% | - | - | - | - | 1件: 65 65 |
290 | Immune Globulin Intravenous | - | - | - | - | 1件: 65 65 |
291 | Immune Globulin Intravenous (Human) | - | - | - | - | 1件: 65 65 |
292 | Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™ | - | - | - | - | 1件: 65 65 |
293 | Immune Globulin Intravenous (human), 10% | - | - | - | - | 2件: 14 14, 65 |
294 | Immune Globulin Intravenous (Human), 10% Solution | - | - | - | - | 1件: 65 65 |
295 | Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution | - | - | - | - | 1件: 65 65 |
296 | Immune Globulin Intravenous (IGIV) | - | - | - | - | 1件: 65 65 |
297 | Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified | - | - | - | - | 1件: 65 65 |
298 | Immune Globulin Subcutaneos, 20% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
299 | Immune Globulin Subcutaneous (Human) | - | - | - | - | 2件: 14 14, 65 |
300 | Immune Globulin Subcutaneous (Human) (SCIG) | - | - | - | - | 1件: 65 65 |
301 | Immune Globulin Subcutaneous (Human), 20% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
302 | Immune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%) | - | - | - | - | 1件: 65 65 |
303 | Immune Globulin Subcutaneous (Human), 20% Solution | - | - | - | - | 1件: 65 65 |
304 | Immune Globulin Subcutaneous (Human), 20%, Caprylate/Chromatography Purified | - | - | - | - | 1件: 65 65 |
305 | Immune Globulin Subcutaneous, 20% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
306 | Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%) | - | - | - | - | 1件: 65 65 |
307 | Immunglobulin (human) | - | - | - | - | 1件: 65 65 |
308 | IMMUNOGLOBULIN G | - | - | - | - | 8件: 2 2, 11, 13, 14, 49, 50, 63, 65 |
309 | Immunoglobulin G (Ig NextGen 16%) | - | - | - | - | 1件: 65 65 |
310 | Immunoglobulin intravenous (human) | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
311 | IMMUNOGLOBULINA UMANA NORMALE | - | - | - | - | 2件: 51 51, 65 |
312 | Immunoglobulins Intravenous (Human) | - | - | - | - | 1件: 65 65 |
313 | Immunoglobulins, normal human | - | - | - | - | 1件: 65 65 |
314 | Immunological diagnosis tests | - | - | - | - | 1件: 65 65 |
315 | Immunosuppression Only Conditioning | - | - | - | - | 1件: 65 65 |
316 | Immunosuppression Only Conditioning -Closed with amendment L | - | - | - | - | 1件: 65 65 |
317 | In vitro-treated peripheral blood stem cell transplantation | - | - | - | - | 2件: 60 60, 65 |
318 | Increlex | 1件: Mecasermin Mecasermin | 2件: D03297
D03297
,
D04870
| 2件: GHR GHR, IGF1R 💬 | 33件: AMPK signaling pathway AMPK signaling pathway, Adherens junction, Autophagy - animal, Breast cancer, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Focal adhesion, FoxO signaling pathway, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, JAK-STAT signaling pathway, Long-term depression, Longevity regulating pathway, Longevity regulating pathway - multiple species, MAPK signaling pathway, Melanoma, Neuroactive ligand-receptor interaction, Oocyte meiosis, Ovarian steroidogenesis, PI3K-Akt signaling pathway, Pathways in cancer, Progesterone-mediated oocyte maturation, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Signaling pathways regulating pluripotency of stem cells, Transcriptional misregulation in cancer, mTOR signaling pathway 💬 | 4件: 65 65, 78, 96, 299 |
319 | Infliximab | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 26件: 35 35, 37, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 55, 56, 65, 84, 95, 96, 97, 98, 107, 162, 164, 269, 270, 271 |
320 | INH | - | - | - | - | 1件: 65 65 |
321 | Interferon Gamma | 1件: Interferon Gamma Interferon Gamma | - | - | - | 8件: 18 18, 65, 85, 107, 228, 299, 301, 326 |
322 | INTERFERON GAMMA-1B | 2件: Interferon Gamma Interferon Gamma, Interferon gamma-1b | 1件: D00747
D00747
| 2件: IFNGR1 IFNGR1, IFNGR2 💬 | 18件: Chagas disease Chagas disease, Cytokine-cytokine receptor interaction, HIF-1 signaling pathway, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 7件: 18 18, 65, 85, 228, 299, 301, 326 |
323 | Interferon-gamma | - | - | - | - | 1件: 65 65 |
324 | INTERLEUKIN-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 8件: 2 2, 35, 49, 55, 65, 96, 97, 162 |
325 | Intratect | - | - | - | - | 4件: 13 13, 14, 35, 65 |
326 | Intravenous immunoglobulin infusion | - | - | - | - | 1件: 65 65 |
327 | Intravenous infusion of transduced cells | - | - | - | - | 1件: 65 65 |
328 | Isolex 300i Magnetic Cell Selector | - | - | - | - | 1件: 65 65 |
329 | Itraconazole | 1件: Itraconazole Itraconazole | 1件: D00350
D00350
| - | - | 5件: 3 3, 65, 96, 227, 299 |
330 | IV treatment with IGSC, 10% | - | - | - | - | 1件: 65 65 |
331 | IVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 8件: 11 11, 13, 14, 17, 35, 50, 51, 65 |
332 | IVIG-PEG | - | - | - | - | 1件: 65 65 |
333 | Jardiance | 1件: Empagliflozin Empagliflozin | 1件: D10459
D10459
| 1件: SLC5A2 SLC5A2 💬 | - | 1件: 65 65 |
334 | Kedrion IVIG 10% | - | - | - | - | 1件: 65 65 |
335 | KIg10 | - | - | - | - | 1件: 65 65 |
336 | Kineret | 1件: Anakinra Anakinra | 1件: D02934
D02934
| 2件: IL1R1 IL1R1, IL1R2 💬 | 15件: Amoebiasis Amoebiasis, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Inflammatory mediator regulation of TRP channels, MAPK signaling pathway, NF-kappa B signaling pathway, Osteoclast differentiation, Pathogenic Escherichia coli infection, Prostate cancer, Shigellosis, Th17 cell differentiation, Transcriptional misregulation in cancer 💬 | 9件: 28 28, 41, 46, 49, 65, 106, 107, 266, 299 |
337 | KIOVIG | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 |
338 | KIOVIG 100 mg/ml solution for infusion | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 2件: 14 14, 65 |
339 | KLH | - | - | - | - | 2件: 13 13, 65 |
340 | KVD824 | - | - | - | - | 1件: 65 65 |
341 | KVD824 300 mg Compresse a rilascio modificato | - | - | - | - | 1件: 65 65 |
342 | KVD824 300 mg Modified Release Tablets | 1件: Manganese citrate Manganese citrate | - | - | - | 1件: 65 65 |
343 | KVD824 hydrochloride | - | - | - | - | 1件: 65 65 |
344 | KVD900 | - | - | - | - | 1件: 65 65 |
345 | KVD900 100 mg Film Coated Tablet | - | - | - | - | 1件: 65 65 |
346 | KVD900 300 mg | - | - | - | - | 1件: 65 65 |
347 | KVD900 600 mg | - | - | - | - | 1件: 65 65 |
348 | L-Arginin | 1件: Arginine Arginine | 1件: D02982
D02982
| - | - | 1件: 65 65 |
349 | L-Arginin-hydrochlorid-einmolar Fresenius | 1件: Arginine Arginine | 1件: D02982
D02982
| - | - | 1件: 65 65 |
350 | L-asparaginase | 1件: Asparaginase Escherichia coli Asparaginase Escherichia coli | 1件: D02997
D02997
| - | - | 1件: 65 65 |
351 | L-fucose | 1件: Fucose Fucose | - | - | - | 1件: 65 65 |
352 | LADICell | - | - | - | - | 1件: 65 65 |
353 | Lapine T-Lymphocyte Immune Globulin | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 4件: 62 62, 65, 283, 286 |
354 | LDT | - | - | - | - | 1件: 65 65 |
355 | Lemtrada | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 2件: 13 13, 65 |
356 | Leniolisib | 1件: Leniolisib Leniolisib | 1件: D11158
D11158
| 3件: PIK3CA PIK3CA, PIK3CB, PIK3CD 💬 | 106件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, AMPK signaling pathway, Acute myeloid leukemia, Aldosterone-regulated sodium reabsorption, Alzheimer disease, Amoebiasis, Apoptosis, Autophagy - animal, Axon guidance, B cell receptor signaling pathway, Bacterial invasion of epithelial cells, Breast cancer, C-type lectin receptor signaling pathway, Carbohydrate digestion and absorption, Cellular senescence, Central carbon metabolism in cancer, Chagas disease, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Choline metabolism in cancer, Cholinergic synapse, Chronic myeloid leukemia, Colorectal cancer, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endometrial cancer, Epstein-Barr virus infection, ErbB signaling pathway, Estrogen signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Gastric cancer, Glioma, GnRH secretion, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatitis B, Hepatitis C, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory mediator regulation of TRP channels, Influenza A, Inositol phosphate metabolism, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Longevity regulating pathway, Longevity regulating pathway - multiple species, Measles, Melanoma, Metabolic pathways, MicroRNAs in cancer, Natural killer cell mediated cytotoxicity, Neurotrophin signaling pathway, Neutrophil extracellular trap formation, Non-alcoholic fatty liver disease, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Phosphatidylinositol signaling system, Phospholipase D signaling pathway, Platelet activation, Platinum drug resistance, Prion disease, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Regulation of lipolysis in adipocytes, Relaxin signaling pathway, Renal cell carcinoma, Salmonella infection, Shigellosis, Signaling pathways regulating pluripotency of stem cells, Small cell lung cancer, Sphingolipid signaling pathway, Spinocerebellar ataxia, T cell receptor signaling pathway, TNF signaling pathway, Thyroid hormone signaling pathway, Toll-like receptor signaling pathway, Type II diabetes mellitus, VEGF signaling pathway, Viral carcinogenesis, Yersinia infection, cAMP signaling pathway, mTOR signaling pathway 💬 | 2件: 53 53, 65 |
357 | Lenograstim | 1件: Lenograstim Lenograstim | 1件: D03247
D03247
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 7件: 2 2, 13, 16, 18, 19, 57, 65 |
358 | Lentiviral G1XCGD Gene Therapy | - | - | - | - | 1件: 65 65 |
359 | Lentiviral vector transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
360 | Leucine | 1件: Leucine Leucine | 1件: D00030
D00030
| - | - | 11件: 5 5, 6, 7, 19, 65, 96, 97, 127, 283, 284, 299 |
361 | LFB-IgSC | - | - | - | - | 1件: 65 65 |
362 | MabThera | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 22件: 11 11, 13, 14, 19, 35, 43, 44, 46, 49, 50, 51, 52, 53, 61, 63, 64, 65, 83, 93, 162, 222, 271 |
363 | MABTHERA - 2 FIALE 100 MG 10 ML | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 19 19, 65 |
364 | Mavorixafor | - | - | - | - | 1件: 65 65 |
365 | MBM-01 | - | - | - | - | 1件: 65 65 |
366 | MCTLs | - | - | - | - | 1件: 65 65 |
367 | Melarsoprol | 1件: Melarsoprol Melarsoprol | 1件: D00832
D00832
| - | - | 1件: 65 65 |
368 | Melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d | 2件: Eflornithine Eflornithine, Melarsoprol | 2件: D00832
D00832
,
D07883
| 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 |
369 | Melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d | 2件: Melarsoprol Melarsoprol, Nifurtimox | 2件: D00832
D00832
,
D00833
| - | - | 1件: 65 65 |
370 | Melphalan | 1件: Melphalan Melphalan | 1件: D00369
D00369
| - | - | 15件: 11 11, 13, 14, 19, 20, 28, 60, 62, 65, 96, 164, 234, 284, 285, 299 |
371 | Mercaptopurine | 1件: Mercaptopurine Mercaptopurine | 2件: D00161
D00161
,
D04931
| 1件: HPRT1 HPRT1 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 4件: 65 65, 96, 97, 164 |
372 | Mesna | 1件: Coenzyme M Coenzyme M | - | - | - | 11件: 11 11, 13, 44, 45, 49, 51, 60, 65, 85, 96, 164 |
373 | Metformin | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 24件: 2 2, 6, 8, 13, 46, 49, 60, 65, 67, 75, 77, 81, 86, 97, 113, 127, 158, 206, 225, 233, 265, 285, 299, 301 |
374 | Methotrexate | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 38件: 11 11, 13, 19, 34, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 107, 162, 164, 172, 256, 270, 271, 283, 284, 285, 286, 326, 331 |
375 | Methylprednisolone | 1件: Methylprednisolone Methylprednisolone | 6件: D00407
D00407
,
D00751
,
D00979
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 18, 19, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 62, 63, 64, 65, 66, 83, 84, 86, 93, 95, 96, 97, 127, 145, 162, 164, 211, 220, 222, 224, 271, 283, 284, 285, 296, 300 |
376 | Methylprednisolone or Prednisolone | 2件: Methylprednisolone Methylprednisolone, Prednisolone | 14件: D00407
D00407
,
D00472
,
D00751
,
D00979
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
,
D05000
,
D05001
,
D05002
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 65 65 |
377 | Miltenyi CliniMACS | - | - | - | - | 3件: 62 62, 65, 285 |
378 | Miltenyi CliniMACS selection system | - | - | - | - | 1件: 65 65 |
379 | MMF | - | - | - | - | 15件: 13 13, 35, 40, 46, 49, 50, 51, 60, 65, 66, 162, 222, 224, 226, 299 |
380 | MONITOR | 1件: Methamidophos Methamidophos | - | - | - | 20件: 2 2, 11, 13, 19, 28, 46, 49, 58, 65, 70, 81, 85, 86, 98, 113, 118, 129, 298, 299, 300 |
381 | Mozobil | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 19 19, 65, 285 |
382 | MOZOBIL - 20 MG/ML - SOLUZIONE INIETTABILE - USO SOTTOCUTANEO - FLACONCINO (VETRO) - 24 MG/1.2 ML 1 FLACONCINO | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 |
383 | Mozobil 20mg/mL vial (injectable solution for subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 |
384 | Mozobil 20mg/mL vial (injectable solution, subcutaneous use) | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 |
385 | Mozobil, | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 |
386 | Mycophenolate | 1件: Mycophenolic acid Mycophenolic acid | 1件: D05096
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 36件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 84, 85, 93, 95, 96, 162, 164, 222, 224, 226, 228, 234, 283, 284, 285, 300 |
387 | Mycophenolate mofetil | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 4件: D00752
D00752
,
D05094
,
D05095
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 34件: 2 2, 11, 13, 19, 20, 28, 35, 36, 42, 43, 44, 45, 49, 51, 53, 60, 61, 62, 65, 66, 85, 93, 95, 96, 162, 164, 222, 224, 226, 234, 283, 284, 285, 300 |
388 | Mycophenolate mofetil (MMF) | 2件: Mycophenolate mofetil Mycophenolate mofetil, Mycophenolic acid | 4件: D00752
D00752
,
D05094
,
D05095
,
D05096
| 2件: IMPDH1 IMPDH1, IMPDH2 💬 | 3件: Drug metabolism - other enzymes Drug metabolism - other enzymes, Metabolic pathways, Purine metabolism 💬 | 7件: 13 13, 49, 51, 60, 65, 66, 222 |
389 | Myeloablative Conditioning-Closed with amendment L | - | - | - | - | 1件: 65 65 |
390 | Myeloablative Preparative Regimen | - | - | - | - | 3件: 62 62, 65, 284 |
391 | MYELOSTIM | - | - | - | - | 1件: 65 65 |
392 | MYELOSTIM - 34 1 FLACONCINO LIOFILIZZATO 33.6 MIU + SIRINGA PRERIEMPITA SOLVENTE 1 ML | - | - | - | - | 2件: 19 19, 65 |
393 | MYELOSTIM 34 milions UI/ml - powder and solvent for solution for injection/infusion | - | - | - | - | 1件: 65 65 |
394 | MYELOSTIM 34 milions UI/ml, powder and solvent for solution for injection or infusion | - | - | - | - | 1件: 65 65 |
395 | N-Acetyl-L-Leucine | 1件: Leucine Leucine | 1件: D00030
D00030
| - | - | 2件: 19 19, 65 |
396 | Nanogam 100 mg/ml | - | - | - | - | 1件: 65 65 |
397 | Nanogam® 50 mg/ml | - | - | - | - | 1件: 65 65 |
398 | NDV-3A | - | - | - | - | 1件: 65 65 |
399 | Neopterin | 1件: Neopterin Neopterin | - | - | - | 1件: 65 65 |
400 | NewGam | - | - | - | - | 3件: 14 14, 63, 65 |
401 | Newnorm | - | - | - | - | 1件: 65 65 |
402 | Nicotinamide | 1件: Nicotinamide Nicotinamide | 1件: D00036
D00036
| - | - | 8件: 2 2, 6, 18, 49, 65, 107, 162, 191 |
403 | Nicotinamide ribonucleoside | 1件: Nicotinamide Nicotinamide | 1件: D00036
D00036
| - | - | 1件: 65 65 |
404 | Nifurtimox | 1件: Nifurtimox Nifurtimox | 1件: D00833
D00833
| - | - | 1件: 65 65 |
405 | Nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d | 2件: Eflornithine Eflornithine, Nifurtimox | 2件: D00833
D00833
,
D07883
| 1件: ODC1 ODC1 💬 | 3件: Arginine and proline metabolism Arginine and proline metabolism, Glutathione metabolism, Metabolic pathways 💬 | 1件: 65 65 |
406 | Nifurtimox-Eflronithine Combination Treatment (NECT) | 1件: Nifurtimox Nifurtimox | 1件: D00833
D00833
| - | - | 1件: 65 65 |
407 | None | - | - | - | - | 16件: 6 6, 46, 51, 65, 78, 84, 85, 96, 97, 140, 160, 161, 171, 231, 271, 299 |
408 | Nonmyeloablative allogeneic hematopoietic stem cell transplantation | - | - | - | - | 6件: 28 28, 51, 60, 62, 65, 285 |
409 | Normal human immunoglobulin G | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
410 | Norovirus -specific T-cell (NST) therapy | - | - | - | - | 1件: 65 65 |
411 | Noxafil | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 3件: 60 60, 65, 299 |
412 | Noxafil 40 mg/ml oral solution | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 65 65 |
413 | NutropinAq 10mg/2ml (30 I.E.) Injektionsllösung | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 65 65 |
414 | OCTA-C1-INH | 1件: Human C1-esterase inhibitor Human C1-esterase inhibitor | - | - | - | 1件: 65 65 |
415 | Octagam | - | - | - | - | 2件: 13 13, 65 |
416 | Octagam 10% | - | - | - | - | 3件: 50 50, 63, 65 |
417 | Octagam 5% | - | - | - | - | 2件: 13 13, 65 |
418 | OCTAGAM 50 mg/ml oldatos infúzió | - | - | - | - | 1件: 65 65 |
419 | Octanorm | - | - | - | - | 2件: 50 50, 65 |
420 | Octanorm 16.5% | - | - | - | - | 2件: 50 50, 65 |
421 | OMALIZUMAB | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 7件: 46 46, 53, 65, 98, 162, 226, 299 |
422 | Omalizumab (Xolair) | 1件: Omalizumab Omalizumab | 1件: D05251
D05251
| 1件: FCER1A FCER1A 💬 | 4件: Asthma Asthma, Fc epsilon RI signaling pathway, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬 | 1件: 65 65 |
423 | ORENCIA | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 14件: 44 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 160, 222, 271 |
424 | ORENCIA® 125 mg solution for injection in pre-filled syringe | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 1件: 65 65 |
425 | Other hematological Agents | - | - | - | - | 1件: 65 65 |
426 | Other: | - | - | - | - | 2件: 2 2, 65 |
427 | Other: 0.9% sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 1件: 65 65 |
428 | Other: Blood sampling for Laboratory Developed Test (LDT) analysis | - | - | - | - | 1件: 65 65 |
429 | Other: Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation | - | - | - | - | 1件: 65 65 |
430 | Other: Cultured Thymus Tissue Implantation with Parathyroid Transplantation | - | - | - | - | 1件: 65 65 |
431 | Other: Donor Lymphocyte Infusion | - | - | - | - | 1件: 65 65 |
432 | Other: Food Diary | - | - | - | - | 1件: 65 65 |
433 | Other: Haematopoietic Stem Cell Transplantation (HSCT) | - | - | - | - | 1件: 65 65 |
434 | Other: Laboratory Biomarker Analysis | - | - | - | - | 21件: 11 11, 13, 14, 26, 28, 34, 49, 51, 60, 62, 65, 89, 96, 97, 205, 232, 283, 284, 285, 298, 331 |
435 | Other: Medical History Questionnaires | - | - | - | - | 1件: 65 65 |
436 | Other: Modified Mixed Meal Tolerance Test | - | - | - | - | 1件: 65 65 |
437 | Other: Modified Oral Glucose Tolerance Test | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 65 65 |
438 | Other: Palliative Care | - | - | - | - | 5件: 19 19, 65, 120, 160, 326 |
439 | Other: Quality-of-Life Assessment | - | - | - | - | 9件: 34 34, 36, 51, 62, 65, 96, 283, 286, 298 |
440 | OTL-101 | - | - | - | - | 1件: 65 65 |
441 | OTL-103 | - | - | - | - | 1件: 65 65 |
442 | OTL-103 Dispersion for Infusion | - | - | - | - | 1件: 65 65 |
443 | OVASTAT | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
444 | Ovastat 1000 | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
445 | Ovastat 1000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
446 | Ovastat 1000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
447 | Ovastat 5000 | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 2件: 13 13, 65 |
448 | Ovastat 5000 (Treosulfan injection) | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
449 | Ovastat 5000 mg, powder for solution for infusion | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 1件: 65 65 |
450 | Palifermin | 1件: Palifermin Palifermin | 1件: D05338
D05338
| 1件: FGFR2 FGFR2 💬 | 13件: Calcium signaling pathway Calcium signaling pathway, Central carbon metabolism in cancer, EGFR tyrosine kinase inhibitor resistance, Endocytosis, Gastric cancer, MAPK signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Signaling pathways regulating pluripotency of stem cells 💬 | 5件: 13 13, 36, 38, 39, 65 |
451 | Pantoprazole | 1件: Pantoprazole Pantoprazole | 2件: D02593
D02593
,
D05353
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 2件: 13 13, 65 |
452 | Pantoprazolo 20 mg gastro-resistant tablets | - | - | - | - | 1件: 65 65 |
453 | PEG | - | - | - | - | 12件: 6 6, 13, 41, 46, 65, 78, 96, 97, 140, 144, 240, 299 |
454 | Peg-Ada | - | - | - | - | 1件: 65 65 |
455 | PEG-ADA ERT | - | - | - | - | 1件: 65 65 |
456 | PEG-interleukin-2 | 1件: Human interleukin-2 Human interleukin-2 | - | - | - | 1件: 65 65 |
457 | Pentamidine | 1件: Pentamidine Pentamidine | 2件: D00834
D00834
,
D08333
| - | - | 2件: 61 61, 65 |
458 | Peripheral Blood Stem Cell Transplantation | - | - | - | - | 12件: 11 11, 13, 14, 28, 51, 60, 62, 65, 283, 284, 285, 286 |
459 | Peripheral Blood Stem Cells | - | - | - | - | 2件: 51 51, 65 |
460 | PHA-022121 | - | - | - | - | 1件: 65 65 |
461 | Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells | - | - | - | - | 1件: 65 65 |
462 | Phosphate | 1件: Phosphate ion Phosphate ion | - | - | - | 33件: 2 2, 3, 6, 11, 12, 13, 15, 28, 36, 46, 49, 51, 53, 60, 62, 65, 70, 78, 81, 83, 90, 96, 97, 164, 235, 238, 256, 276, 283, 284, 285, 286, 299 |
463 | PHVS416 | - | - | - | - | 1件: 65 65 |
464 | PID | - | - | - | - | 1件: 65 65 |
465 | Pioglitazone | 1件: Pioglitazone Pioglitazone | 2件: D00945
D00945
,
D08378
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 17件: 2 2, 6, 13, 15, 20, 46, 49, 65, 67, 78, 81, 86, 96, 229, 265, 298, 299 |
466 | PLERIXAFOR | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 5件: 20 20, 51, 65, 285, 299 |
467 | Plerixafor for Conditioning before HSCT. | 1件: Plerixafor Plerixafor | 1件: D08971
D08971
| 1件: CXCR4 CXCR4 💬 | 12件: Axon guidance Axon guidance, Calcium signaling pathway, Chemokine signaling pathway, Cytokine-cytokine receptor interaction, Endocytosis, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Intestinal immune network for IgA production, Leukocyte transendothelial migration, Pathways in cancer, Regulation of actin cytoskeleton, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 |
468 | PnCJ PPS | - | - | - | - | 1件: 65 65 |
469 | PNEUMO 23 | - | - | - | - | 1件: 65 65 |
470 | Pneumovax® (pneumococcal polysaccharide vaccine) | - | - | - | - | 1件: 65 65 |
471 | Polyclonal IgG | - | - | - | - | 1件: 65 65 |
472 | Posaconazole | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 4件: 60 60, 65, 96, 299 |
473 | Posaconazole (PSZ) | 1件: Posaconazole Posaconazole | 1件: D02555
D02555
| - | - | 1件: 65 65 |
474 | PPS | - | - | - | - | 1件: 65 65 |
475 | PREDNISOLONE | 1件: Prednisolone Prednisolone | 8件: D00472
D00472
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 43件: 3 3, 11, 13, 14, 25, 26, 35, 38, 39, 40, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 107, 113, 145, 162, 222, 269, 271, 296, 299, 300, 307 |
476 | Prednisone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 48件: 2 2, 6, 11, 13, 14, 19, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 79, 81, 84, 85, 86, 95, 96, 97, 113, 127, 162, 164, 205, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
477 | PREVENAR | - | - | - | - | 1件: 65 65 |
478 | Prevenar® (7-valent pneumococcal conjugate vaccine) | - | - | - | - | 1件: 65 65 |
479 | PRIVIGEN | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 4件: 11 11, 14, 51, 65 |
480 | Privigen® | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 3件: 14 14, 63, 65 |
481 | Procarbazine | 1件: Procarbazine Procarbazine | 2件: D00478
D00478
,
D08423
| - | - | 1件: 65 65 |
482 | Progynova 21 mite | - | - | - | - | 1件: 65 65 |
483 | Proleukin | 1件: Aldesleukin Aldesleukin | 1件: D00748
D00748
| 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 3件: 2 2, 49, 65 |
484 | PROLEUKIN® S | 1件: Aldesleukin Aldesleukin | 1件: D00748
D00748
| 3件: IL2RA IL2RA, IL2RB, IL2RG 💬 | 14件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Inflammatory bowel disease, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Primary immunodeficiency, Th1 and Th2 cell differentiation, Th17 cell differentiation, Transcriptional misregulation in cancer, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 65 65 |
485 | Promacta | 1件: Eltrombopag Eltrombopag | - | - | - | 2件: 63 63, 65 |
486 | Prometic's Immune Globulin Intravenous 10% | - | - | - | - | 1件: 65 65 |
487 | PSRS11.EFS.IL2RG.pre* retroviral vector | - | - | - | - | 1件: 65 65 |
488 | PSRS11.EFS.IL2RG.pre* retroviral vector transduce | - | - | - | - | 1件: 65 65 |
489 | PSRS11.EFS.IL2RG.pre* retroviral vector transduced cells | - | - | - | - | 1件: 65 65 |
490 | PTH | - | - | - | - | 2件: 65 65, 235 |
491 | PTH 1-34 | 1件: Teriparatide Teriparatide | 1件: D06078
D06078
| 1件: PTH1R PTH1R 💬 | 3件: Endocrine and other factor-regulated calcium reabsorption Endocrine and other factor-regulated calcium reabsorption, Neuroactive ligand-receptor interaction, Parathyroid hormone synthesis, secretion and action 💬 | 2件: 65 65, 235 |
492 | Purified Vero Cell Vaccine) | - | - | - | - | 1件: 65 65 |
493 | PYRIMETHAMINE | 1件: Pyrimethamine Pyrimethamine | 1件: D00488
D00488
| - | - | 4件: 2 2, 4, 19, 65 |
494 | R-hIL-18BP | - | - | - | - | 1件: 65 65 |
495 | Rabbit | 1件: Rabbit Rabbit | - | - | - | 8件: 11 11, 13, 49, 51, 60, 65, 96, 285 |
496 | Rabbit anti-thymocyte globulin | 1件: Rabbit Rabbit | - | - | - | 2件: 49 49, 65 |
497 | Radiation: radiation therapy | - | - | - | - | 5件: 34 34, 60, 65, 284, 285 |
498 | Radiation: Total body 200cGy | - | - | - | - | 1件: 65 65 |
499 | Radiation: Total Body Irradiation | - | - | - | - | 7件: 36 36, 49, 51, 60, 65, 283, 284 |
500 | Radiation: Total Body Irradiation (TBI) | - | - | - | - | 3件: 60 60, 65, 285 |
501 | Radiation: total-body irradiation | - | - | - | - | 9件: 28 28, 51, 60, 62, 65, 96, 283, 284, 285 |
502 | RAG1 LV CD34+ cells | - | - | - | - | 1件: 65 65 |
503 | Ranitidine | 1件: Ranitidine Ranitidine | 2件: D00422
D00422
,
D00673
| 1件: HRH2 HRH2 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Gastric acid secretion, Neuroactive ligand-receptor interaction 💬 | 2件: 13 13, 65 |
504 | Recombinant human hyaluronidase | 1件: Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) | - | - | - | 3件: 14 14, 28, 65 |
505 | Recombinant Human Hyaluronidase (rHuPH20) | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
506 | Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV) | 1件: Hyaluronidase (human recombinant) Hyaluronidase (human recombinant) | - | - | - | 1件: 65 65 |
507 | Recombinant human hyaluronidase + immune globulin intravenous | 2件: Hyaluronidase Hyaluronidase, Hyaluronidase (human recombinant) | 3件: D04455
D04455
,
D04456
,
D06604
| - | - | 1件: 65 65 |
508 | Reduced Intensity Conditioning | - | - | - | - | 2件: 19 19, 65 |
509 | Reduced Intensity Preparative Regimen | - | - | - | - | 3件: 62 62, 65, 284 |
510 | Reduced Toxicity Ablative Regimen | - | - | - | - | 3件: 62 62, 65, 284 |
511 | Release | 1件: Manganese citrate Manganese citrate | - | - | - | 12件: 6 6, 8, 13, 46, 65, 78, 81, 96, 97, 206, 226, 299 |
512 | Retroviral SF71-gp91phox transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
513 | Retrovirus-mediated gene transfer | - | - | - | - | 1件: 65 65 |
514 | RhuCD40L | - | - | - | - | 1件: 65 65 |
515 | RI-002 | - | - | - | - | 1件: 65 65 |
516 | Rifaximin | 1件: Rifaximin Rifaximin | 1件: D02554
D02554
| - | - | 7件: 6 6, 65, 93, 96, 97, 99, 296 |
517 | Rimiducid | 1件: Rimiducid Rimiducid | 1件: D11195
D11195
| 1件: CASP9 CASP9 💬 | 35件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Apoptosis, Apoptosis - multiple species, Colorectal cancer, Endometrial cancer, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Huntington disease, Influenza A, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Measles, Non-small cell lung cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parkinson disease, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platinum drug resistance, Prion disease, Prostate cancer, Small cell lung cancer, Thyroid hormone signaling pathway, Toxoplasmosis, Tuberculosis, VEGF signaling pathway, Viral myocarditis, p53 signaling pathway 💬 | 6件: 19 19, 60, 65, 284, 285, 326 |
518 | Rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 49件: 6 6, 11, 13, 14, 17, 19, 35, 36, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 127, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 |
519 | Rituximab (RTX) and Azathioprine (AZA) | 2件: Azathioprine Azathioprine, Rituximab | 3件: D00238
D00238
,
D02994
,
D03033
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 65 65 |
520 | Rivogenlecleucel | - | - | - | - | 6件: 19 19, 60, 65, 284, 285, 326 |
521 | Romiplostim | 1件: Romiplostim Romiplostim | 1件: D08990
D08990
| 1件: MPL MPL 💬 | 2件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, JAK-STAT signaling pathway 💬 | 4件: 60 60, 63, 64, 65 |
522 | RP-L201 | - | - | - | - | 1件: 65 65 |
523 | RTX | - | - | - | - | 5件: 11 11, 46, 65, 222, 240 |
524 | SC treatment with IGSC, 10% with rHuPH20 followed by IV/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 |
525 | SC treatment with IGSC, 10% with rHuPH20 followed by SC/IGSC, 10% only (safety) | - | - | - | - | 1件: 65 65 |
526 | SCID screening | - | - | - | - | 1件: 65 65 |
527 | SCYX-7158 | 1件: SCYX-7158 SCYX-7158 | - | - | - | 1件: 65 65 |
528 | Sirolimus | 1件: Sirolimus Sirolimus | 1件: D00753
D00753
| 1件: MTOR MTOR 💬 | 51件: AMPK signaling pathway AMPK signaling pathway, Acute myeloid leukemia, Adipocytokine signaling pathway, Alzheimer disease, Amyotrophic lateral sclerosis, Apelin signaling pathway, Autophagy - animal, Autophagy - other, Breast cancer, Cellular senescence, Central carbon metabolism in cancer, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Diabetic cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, ErbB signaling pathway, Gastric cancer, Glioma, Growth hormone synthesis, secretion and action, HIF-1 signaling pathway, Hepatocellular carcinoma, Herpes simplex virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Huntington disease, Insulin resistance, Insulin signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Longevity regulating pathway, Longevity regulating pathway - multiple species, MicroRNAs in cancer, Neutrophil extracellular trap formation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Shigellosis, Spinocerebellar ataxia, Th17 cell differentiation, Thermogenesis, Thyroid hormone signaling pathway, Type II diabetes mellitus, mTOR signaling pathway 💬 | 36件: 6 6, 13, 15, 17, 19, 34, 35, 36, 46, 49, 51, 60, 61, 62, 63, 65, 66, 67, 84, 85, 89, 98, 127, 137, 157, 158, 192, 222, 277, 278, 279, 280, 281, 283, 285, 331 |
529 | Sodium chloride | 2件: Chloride ion Chloride ion, Sodium chloride | 1件: D02056
D02056
| - | - | 21件: 6 6, 11, 13, 14, 34, 46, 50, 51, 53, 60, 65, 67, 78, 96, 168, 193, 227, 228, 271, 288, 299 |
530 | Somatic gene-therapy by X-CGD | - | - | - | - | 1件: 65 65 |
531 | Somatotropin | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 4件: 3 3, 65, 78, 236 |
532 | Somatropin | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 19件: 2 2, 3, 19, 46, 65, 74, 75, 78, 96, 107, 113, 187, 193, 195, 238, 265, 274, 276, 299 |
533 | Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate | 5件: Arginine Arginine, Clonidine, Estradiol, Estradiol valerate, Somatotropin | 12件: D00105
D00105
,
D00281
,
D00604
,
D01413
,
D01617
,
D01953
,
D02691
,
D02982
,
D04061
,
D04063
,
D04064
,
D04065
| 6件: ADRA2A ADRA2A, ADRA2B, ADRA2C, ESR1, ESR2, GHR 💬 | 16件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Cytokine-cytokine receptor interaction, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 |
534 | STA-5326 | - | - | - | - | 2件: 65 65, 96 |
535 | Stelara (ustekinumab) | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 65 65 |
536 | Stem Cell Infusion | - | - | - | - | 5件: 28 28, 60, 65, 284, 285 |
537 | Stem Cell Transplant | - | - | - | - | 6件: 19 19, 20, 60, 65, 164, 284 |
538 | Stem Cell Transplantation | - | - | - | - | 13件: 13 13, 19, 20, 46, 51, 60, 62, 65, 90, 125, 164, 234, 326 |
539 | STRIMVELIS | - | - | - | - | 1件: 65 65 |
540 | Subcuvia | - | - | - | - | 3件: 14 14, 49, 65 |
541 | Subgam | - | - | - | - | 1件: 65 65 |
542 | Sulfadoxine | 1件: Sulfadoxine Sulfadoxine | 1件: D00580
D00580
| - | - | 1件: 65 65 |
543 | Suspension of autologous CD34+cells transduced with the G1XCGD viral vector | - | - | - | - | 1件: 65 65 |
544 | T-Cell Depleted & CD34+Select/w/StemCell Enriched Product | - | - | - | - | 1件: 65 65 |
545 | Tabelecleucel | - | - | - | - | 1件: 65 65 |
546 | Tablets Fexinidazole | 1件: Fexinidazole Fexinidazole | 1件: D11252
D11252
| - | - | 1件: 65 65 |
547 | Tacrolimus | 1件: Tacrolimus Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 34件: 2 2, 6, 11, 13, 36, 46, 49, 50, 51, 53, 56, 60, 61, 62, 65, 66, 85, 95, 96, 97, 113, 151, 158, 164, 222, 224, 226, 227, 228, 283, 284, 285, 286, 299 |
548 | Tacrolimus (Tacro) | 1件: Tacrolimus Tacrolimus | 2件: D00107
D00107
,
D08556
| 5件: PPP3CA PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 💬 | 33件: Alzheimer disease Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 65 65 |
549 | TADEKINIG ALFA | 1件: Tadekinig alfa Tadekinig alfa | - | - | - | 1件: 65 65 |
550 | TAK-771 | - | - | - | - | 2件: 14 14, 65 |
551 | TBX-1400 | - | - | - | - | 1件: 65 65 |
552 | TCR alfa beta T cell depletion | - | - | - | - | 1件: 65 65 |
553 | Thalidomide | 1件: Thalidomide Thalidomide | 1件: D00754
D00754
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 20件: 2 2, 16, 20, 28, 49, 51, 53, 56, 65, 84, 85, 94, 96, 97, 227, 271, 280, 298, 300, 331 |
554 | Therapeutic allogeneic lymphocytes | - | - | - | - | 3件: 60 60, 65, 285 |
555 | There is no recommended INN | - | - | - | - | 1件: 65 65 |
556 | Thiotepa | 1件: Thiotepa Thiotepa | 1件: D00583
D00583
| - | - | 12件: 13 13, 19, 20, 28, 51, 60, 65, 85, 96, 164, 284, 285 |
557 | Thiotepa--escalated dose | 1件: Thiotepa Thiotepa | 1件: D00583
D00583
| - | - | 4件: 19 19, 20, 65, 284 |
558 | Thiotepa--single daily dose | 1件: Thiotepa Thiotepa | 1件: D00583
D00583
| - | - | 4件: 19 19, 20, 65, 284 |
559 | Thymafalsin | - | - | - | - | 1件: 65 65 |
560 | THYMALFASIN | 1件: Thymalfasin Thymalfasin | 1件: D06116
D06116
| - | - | 1件: 65 65 |
561 | Thymoglobulin | 1件: Antithymocyte immunoglobulin (rabbit) Antithymocyte immunoglobulin (rabbit) | - | - | - | 7件: 36 36, 51, 60, 65, 96, 285, 326 |
562 | Thymus Tissue for Transplantation | - | - | - | - | 1件: 65 65 |
563 | Thymus/Parathyroid Transplantation | - | - | - | - | 2件: 65 65, 235 |
564 | To be confirmed | - | - | - | - | 3件: 46 46, 65, 97 |
565 | Tofacitinib | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 15件: 11 11, 40, 44, 46, 49, 50, 51, 53, 65, 84, 96, 97, 107, 256, 271 |
566 | Total body Irradiation | - | - | - | - | 6件: 19 19, 20, 51, 60, 65, 285 |
567 | Total lymphoid irradiation | - | - | - | - | 3件: 65 65, 284, 326 |
568 | Traditional treatment of CGD and TB | - | - | - | - | 1件: 65 65 |
569 | Transduced Lymphocytes | - | - | - | - | 1件: 65 65 |
570 | Transduced patient CD34+ cells | - | - | - | - | 1件: 65 65 |
571 | Transplant Conditioning with Mobilization and Alemtuzumab | 1件: Alemtuzumab Alemtuzumab | 1件: D02802
D02802
| 1件: CD52 CD52 💬 | - | 1件: 65 65 |
572 | Transplant Conditioning with Mobilization Only | - | - | - | - | 1件: 65 65 |
573 | Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan | 4件: Alemtuzumab Alemtuzumab, Fludarabine, Melphalan, Thiotepa | 5件: D00369
D00369
,
D00583
,
D01907
,
D02802
,
D07966
| 2件: CD52 CD52, RRM1 💬 | 6件: , Drug metabolism - other enzymes, Glutathione metabolism, Metabolic pathways, Purine metabolism, Pyrimidine metabolism 💬 | 2件: 65 65, 164 |
574 | TREOSULFAN | 1件: Treosulfan Treosulfan | 1件: D07253
D07253
| - | - | 6件: 13 13, 19, 62, 65, 283, 286 |
575 | Triheptanoin | 1件: Triheptanoin Triheptanoin | 1件: D11465
D11465
| - | - | 10件: 2 2, 8, 65, 149, 156, 248, 256, 257, 317, 324 |
576 | TYF-IL-2Rg gene-modified autologous stem cells | - | - | - | - | 1件: 65 65 |
577 | Umbilical Cord Blood Transplantation | - | - | - | - | 5件: 60 60, 65, 284, 285, 326 |
578 | Unrelated BM with T cell depletion | - | - | - | - | 1件: 65 65 |
579 | Unrelated cord blood | - | - | - | - | 1件: 65 65 |
580 | Unrelated PBSC with T cell depletion | - | - | - | - | 1件: 65 65 |
581 | Ustekinumab | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 17件: 37 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 |
582 | Valacyclovir | 1件: Valaciclovir Valaciclovir | 3件: D00398
D00398
,
D08664
,
D10518
| - | - | 1件: 65 65 |
583 | Valproic Acid | 1件: Valproic acid Valproic acid | 1件: D00399
D00399
| 7件: ABAT ABAT, ALDH5A1, CACNA1G, CACNA1H, CACNA1I, GAD1, GAD2 💬 | 17件: Alanine, aspartate and glutamate metabolism Alanine, aspartate and glutamate metabolism, Aldosterone synthesis and secretion, Butanoate metabolism, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GABAergic synapse, GnRH secretion, MAPK signaling pathway, Metabolic pathways, Propanoate metabolism, Taurine and hypotaurine metabolism, Type I diabetes mellitus, Type II diabetes mellitus, Valine, leucine and isoleucine degradation, beta-Alanine metabolism 💬 | 10件: 3 3, 5, 26, 34, 65, 89, 90, 222, 256, 331 |
584 | Verorab® (PVRV | - | - | - | - | 1件: 65 65 |
585 | Vigantol | - | - | - | - | 4件: 13 13, 65, 96, 97 |
586 | Vinblastine | 1件: Vinblastine Vinblastine | 2件: D01068
D01068
,
D08675
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 2件: 34 34, 65 |
587 | Vinblastine, vincristine, prednisone, daunorubicin | 4件: Daunorubicin Daunorubicin, Prednisone, Vinblastine, Vincristine | 7件: D00473
D00473
,
D01068
,
D01264
,
D02197
,
D07776
,
D08675
,
D08679
| 12件: NR3C1 NR3C1, TOP2A, TOP2B, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Neuroactive ligand-receptor interaction, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Platinum drug resistance, Prion disease, Salmonella infection 💬 | 1件: 65 65 |
588 | Vincristine | 1件: Vincristine Vincristine | 2件: D02197
D02197
,
D08679
| 9件: TUBB TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 10件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Gap junction, Huntington disease, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 4件: 26 26, 34, 65, 331 |
589 | Vitamin B3 | - | - | - | - | 2件: 65 65, 107 |
590 | Vitamin D3 | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 12件: 6 6, 13, 20, 46, 49, 51, 53, 60, 65, 96, 97, 299 |
591 | Vivaglobin | - | - | - | - | 2件: 14 14, 65 |
592 | VM106 | - | - | - | - | 1件: 65 65 |
593 | Water | 1件: Water Water | 1件: D00001
D00001
| - | - | 23件: 2 2, 5, 6, 13, 17, 19, 22, 35, 46, 51, 53, 56, 57, 63, 65, 67, 78, 84, 96, 97, 226, 278, 299 |
594 | X4P-001 | - | - | - | - | 1件: 65 65 |
595 | XELJANZ (tofacitinib) | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 65 65 |
596 | Xifaxan | 1件: Rifaximin Rifaximin | 1件: D02554
D02554
| - | - | 2件: 65 65, 94 |
597 | Zadaxin | - | - | - | - | 2件: 65 65, 299 |
598 | ZARZIO | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 3件: 38 38, 65, 285 |
599 | Zoledronate | 1件: Zoledronic acid Zoledronic acid | 4件: D01968
D01968
,
D06378
,
D06379
,
D08689
| 1件: FDPS FDPS 💬 | 4件: Human T-cell leukemia virus 1 infection Human T-cell leukemia virus 1 infection, Influenza A, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 2件: 46 46, 65 |